Cancer Research ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | The UK’s Concordat to Support Research Integrity provides a national framework for good research conduct and its governance. The Concordat is now due to be reviewed to ensure it continues to reflect the views and needs of stakeholders.
You can shape these revisions and help ensure the Concordat is fit for the future, reflects recent developments in research and continues to safeguard research integrity. Submit your views through the short online consultation. |
| | |
| | |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
|
| | |
|
|
Meet the May winner of our #ResearchisBeautiful image campaign |
| Congratulations to Elisa Moutin from our Cambridge Institute for the first winning image of the month in our Research is Beautiful image campaign.
Elisa’s image captures a piece of mouse colon where stem cells and their progeny were marked with different colours using a genetic tool called Confetti.
Think yours measures up? Drop us an email today with your wonderful moments of science. T&Cs apply. |
| | |
|
|
|
| | | | | Researchers at The Royal Marsden and The Institute of Cancer Research have developed a saliva test that could be a better way to identify men at high risk of prostate cancer than the prostate-specific antigen (PSA) test.
Findings from the BARCODE 1 study, presented at ASCO 2024, calculated the prostate cancer polygenic risk score (PRS) of patients recruited. Of these, 40% of the men with a high PRS score were diagnosed with prostate cancer, a significant increase from those identified by the PSA test. The new test also detected that 55% of the cancers in the study were aggressive, improving on the 36% in detected by the PSA test.
The PRSs were based on 130 genetic variations shown to be linked with prostate cancer. | | |
| | | | | | | Kai-Keen Shiu and researchers from University College London have found that giving the immunotherapy drug pembrolizumab before surgery to people with advanced colorectal cancer and specific genetic profiles is highly safe, efficacious and has positive clinical outcomes.
Interim results from the Phase 2 clinical trial presented at ASCO, showed that over 50% of the 32 patients treated with pembrolizumab had no signs of cancer after surgery.
The study conducted by the Cancer Research UK and UCL Cancer Trials Centre also showed that all patients remained cancer-free for several months. These findings lay a strong foundation to further explore the relationship between novel biomarkers and response to pembrolizumab in blood. | | |
|
|---|
|
|
|
|
New at MAP congress: AI in clinical trials day |
| The Molecular Analysis for Precision Oncology (MAP) will once again have the clinically focused ‘RoadMAP to the Clinic’ day which will centre around using AI for drug development. The day will feature lectures and panel discussions on deploying AI at scale and tackling the regulatory challenges of AI in clinical trials.
You also have the chance to present your work as a poster or give a talk as part of the conference programme – the abstract submission deadline is 23 July.
|
| | |
|
|
|
| | | | | The must-attend session chaired by Darren Hargrave (University College London/Great Ormond Street Hospital) will showcase international perspectives, expertise and insights on some of the most prominent issues in the field.
Join Juanita Lopez (The Royal Marsden) to explore disruptive clinical trial design for genomically complex brain tumours. Nader Sanai (Barrow Neurological Institute) will share insights into pharmacokinetic/ pharmacodynamic-driven clinical trials for brain tumours.
Follow our social media channels with #CRUKBrain24 for more updates. | | |
| | | | | | | Are you interested in discussing the latest concepts in cancer prevention research?
Grab your tickets before 11 June to attend a packed three-day event with sessions, panel discussions and debates.
Our first annual conference takes place in Boston on 25-27 June, and is hosted by the American Cancer Society, in collaboration with the National Cancer Institute and us.
Use #PrevConf24 on social media to let us know if you’re joining us.
| | |
|
|---|
|
|
|
|
What did you think of this email? |
|
| | |
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer sooner, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
